BriaCell Therapeutics Corp announced the pricing of a best-efforts public offering of 5,366,726 units.
Each unit consists of one common share (or pre-funded warrant) and one warrant.
The units are priced at $5.59 per unit, resulting in gross proceeds of approximately $30 million.
Unit Composition
Each unit includes one common share and one warrant.
Pricing Details
Units are priced at $5.59 each, with warrants exercisable at $6.93 per share.
Listing Information
Warrants are approved for listing on the Nasdaq Capital Market under the symbol 'BCTXL'.
Offering Closure
The offering is expected to close on January 15, 2026.
Use of Proceeds
Proceeds will fund working capital, corporate purposes, and business objectives.
- The public offering of $30 million will support BriaCell's operational and growth initiatives.
- Listing on the Nasdaq Capital Market under the symbol 'BCTXL' enhances visibility and market presence.
BriaCell's successful pricing of the public offering reflects investor confidence and supports future growth.